These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
447 related items for PubMed ID: 21620416
1. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M, SOLAR study group. J Neurol Sci; 2011 Dec 15; 311(1-2):44-9. PubMed ID: 21620416 [Abstract] [Full Text] [Related]
2. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M. Mult Scler; 2010 Jul 15; 16(7):848-54. PubMed ID: 20488825 [Abstract] [Full Text] [Related]
3. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a. Hupperts R, Smolders J, Vieth R, Holmøy T, Marhardt K, Schluep M, Killestein J, Barkhof F, Beelke M, Grimaldi LME, SOLAR Study Group. Neurology; 2019 Nov 12; 93(20):e1906-e1916. PubMed ID: 31594857 [Abstract] [Full Text] [Related]
6. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ. Arch Neurol; 2008 Feb 12; 65(2):199-204. PubMed ID: 18071030 [Abstract] [Full Text] [Related]
7. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ. Neurology; 2011 Oct 25; 77(17):1611-8. PubMed ID: 22025459 [Abstract] [Full Text] [Related]
8. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB, SIMCOMBIN study investigators. Lancet Neurol; 2011 Aug 25; 10(8):691-701. PubMed ID: 21742556 [Abstract] [Full Text] [Related]
9. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D. Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959 [Abstract] [Full Text] [Related]
18. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan. Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282 [Abstract] [Full Text] [Related]